Elecoglipron
Embold
AstraZeneca · Phase 3 · Recruiting · Enrollment 4500
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Arm 1 - Dose 1 | n/r | n/r | n/r | n/r |
| Arm 2 - Dose 2 | n/r | n/r | n/r | n/r |
| Arm 3 - Placebo | n/r | n/r | n/r | n/r |
Not shown
- Arm 1 - Dose 1: endpoint not reported
- Arm 2 - Dose 2: endpoint not reported
- Arm 3 - Placebo: endpoint not reported